Variable impact of dupilumab on patch testing results and allergic contact dermatitis in adults with atopic dermatitis - 21/06/19
Abstract |
Background |
Previous case reports and series suggested that dupilumab may be an effective treatment for allergic contact dermatitis (ACD). Little is known about the impact of dupilumab on patch test results and comorbid ACD in patients with atopic dermatitis (AD).
Objective |
Determine the impact of dupilumab on patch testing results and improvement of ACD in patients with AD.
Methods |
A retrospective study of patients with AD treated with dupilumab who underwent patch testing (n = 7) or had concomitant ACD (n = 6).
Results |
In all, 7 patients with AD were patch tested while taking dupilumab; in all of these patients, at least 1 positive patch test reaction was observed, with a total of 25 different allergens having a reaction graded as 1+ or stronger and few irritant reactions. In 1 patient, multiple previously positive relevant patch test results were not duplicated upon repeat patch testing. In the 6 patients with AD and concomitant ACD, dupilumab and allergen avoidance resulted in substantial or complete resolution of AD signs and symptoms but resolution of ACD in only 3 patients. However, 3 patients had at least 1 flare of ACD upon re-exposure to relevant allergens.
Limitations |
Retrospective and uncontrolled study.
Conclusions |
Dupilumab had variable impact on patch testing results and resolution of comorbid ACD in adult patients with AD.
Le texte complet de cet article est disponible en PDF.Key words : allergic contact dermatitis, atopic dermatitis, biologic, eczema, treatment
Abbreviations used : ACD, AD, BSA, IL, Th
Plan
| Funding sources: None. |
|
| Disclosure: Dr Silverberg has served as a consultant and/or advisory board member for AbbVie, AnaptysBio, Asana, Arena, Boehringer Ingelheim, Dermavant, Eli Lilly and Company, Galderma, GlaxoSmithKline, Glenmark, Kiniksa, Leo, Menlo, Novartis, Pfizer, Regeneron-Sanofi, and Realm, receiving honoraria; has served as a speaker for Regeneron-Sanofi; and has received research grants from GlaxoSmithKline. Dr Stout has no conflicts of interest to disclose. |
|
| Dr Stout and Dr Silverberg had full access to all of the data in the study and take responsibility for the integrity of the data. Dr Stout and Dr Silverberg take responsibility for acquisition, analysis, and interpretation of data; drafting of the article; and critical revision of the article for important intellectual content. Dr Silverberg takes responsibility for the study concept and design. |
|
| Reprints not available from the authors. |
Vol 81 - N° 1
P. 157-162 - juillet 2019 Retour au numéro
Article précédent
- Prevalence estimates for chronic urticaria in the United States: A sex- and age-adjusted population analysis
- Sara Wertenteil, Andrew Strunk, Amit Garg
- Sexual dysfunction in men taking systemic dermatologic medication: A systematic review
- George A. Zakhem, Julia E. Goldberg, Catherine C. Motosko, Brandon E. Cohen, Roger S. Ho
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?